参附注射液联合丹参酮 ⅡA磺酸钠注射液治疗慢性阻塞性肺疾病急性加重期
王静,杨宝江,常银竹,张洪玉
(北京市房山区中医医院肺病科,北京 102400)
摘要:目的观察参附注射液联合丹参酮 ⅡA磺酸钠注射液治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法150例患者随机分为2组,治疗组和对照组各75例。2组患者均予控制性氧疗、抗感染、支气管扩张剂、糖皮质激素、营养支持等基础治疗。治疗组在上述治疗基础上加用参附注射液、丹参酮 ⅡA磺酸钠注射液静脉滴注,1次/d,共14 d。观察2组患者治疗前后临床疗效、肺功能、动脉血气分析指标、血液流变学及BODE指数、主要症状等相关因素的改善情况。结果治疗组与对照组有效率分别为88.00%和73.33%。治疗组在一定程度上有效增加了肺活量(VC)、1秒钟用力呼气容积与预计值比值(FEV1/Pre%)和1秒钟用力呼气容积与用力肺活量比值(FEV1/FVC%)(P<0.05),降低二氧化碳分压(PaCO2),提高氧分压(PaO2)(P<0.05),有效降低全血低切黏度、全血高切黏度、红细胞沉降率等血液流变学指标(P<0.05),有效改善BODE指数各因子(P<0.05),并显著改善了患者临床症状。结论参附注射液联合丹参酮 ⅡA磺酸钠注射液通过纠正患者血液流变学异常,改善微循环,增加PaO2,降低PaCO2缓解症状,降低BODE指数,改善预后,提高患者生存质量。
关键词:参附注射液;丹参酮ⅡA磺酸钠注射液;慢性阻塞性肺疾病;急性加重期
DOI::10.13463/j.cnki.jlzyy.2015.07.015
中图分类号:R256.1文献标志码: A
文章编号:1003-5699(2015)07-0696-05
基金项目:北京市科委资助项目(Z141107002514083)。
作者简介:王静(1973-),女,大学本科,副主任医师,主要从事呼吸系统疾病的中西医结合治疗。

Shenfu Injection combined with Sulfotanshinone Sodium Injection treatment of chronic
obstructive pulmonary disease in acute exacerbation
WANG Jing,YANG Baojiang,CHANG Yinzhu,ZHANG Hongyu
(Department of Pulmonology,Fangshan District Hospital of Traditional Chinese Medicine,Beijing 102400,China)
Abstract:ObjectiveTo observe the clinical efficacy of Shenfu Injection combined with Sulfotanshinone Sodium Injection in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease.MethodsThe 150 cases patients were randomly divided into treatment group and control group,respectively in 75 cases.All patients were given combined therapy such as oxygen treatment,anti-infection,bronchodilator,glucocorticoid and nutritional foundation treatment,etc.On the basic of which,the treatment group was given extra Shenfu Injection and Sulfotanshinone Sodium Injection intravenously,one time a day,14 days in total.Observed the clinical effect,lung function,arterial blood and qi analysis index,hemorheology,and BODE factors,main symptoms changes before and after treatment.ResultsThe efficacy rate of the treatment group was 88.00%,and that of the control group was 73.33%.Compared with control group,the treatment group could significantly improve VC,FEV1/Pre% and FEV1/FVC% (P<0.05),decrease PaCO2 and hemorheology related factors including blood viscosity,erythrocyte sedimentation rate and so on,also improve PaO2 and Body factors (P<0.05).Effectively improve the BODE index factor (P<0.05),as well as improving the patients’ symptoms.ConclusionThe combination of Shenfu Injection and Sulfotanshinone Sodium Injection through correct abnormal hemorheology of patients,improve the microcirculation,improve PaO2 and decrease PaCO2,improve the BODE index factor to improve patients’ life quality.
Keywords:Shenfu Injection;Sulfotanshinone Sodium Injection;chronic obstructive pulmonary disease;acute exacerbation
慢性阻塞性肺疾病(COPD)是一种可防治的常见疾病。该病是以气流受限为基本特征的慢性呼吸系统疾病,气流受限程度为不完全可逆,呈进行性发展,伴有肺和气道对有害气体或颗粒所致慢性炎症反应[1]。中医认为,COPD属于“咳嗽”“哮病”“喘证”“肺胀”等范畴,其发病机制为本虚标实。急性期以标实为主,其特点是肺脏反复受邪,损伤肺气导致气机升降失司,以瘀血、热、痰浊较为常见。……